Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia

We read with great interest the article by Rinella et al. published in the Journal of Hepatology.1 In 2023, the non-alcoholic fatty liver disease (NAFLD) Nomenclature Consensus Group published a multi-society Delphi consensus statement on new fatty liver disease nomenclature. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD).1 MASLD is defined as a combination of hepatic steatosis and the presence of at least one of five cardiometabolic risk factors.